MeSH term
Frequency | Condition_Probility | *Cleavage Stage, Ovum | 2 | 1.0 |
Embryo Transfer/*standards | 2 | 1.0 |
Female | 54 | 0.0 |
Humans | 131 | 0.0 |
Meta-Analysis | 2 | 1.0 |
Pregnancy | 2 | 0.0 |
Pregnancy Outcome | 2 | 0.0 |
Pregnancy Rate | 2 | 1.0 |
Pregnancy, Multiple | 2 | 1.0 |
Randomized Controlled Trials | 2 | 0.0 |
Review Literature | 2 | 1.0 |
Adult | 37 | 0.0 |
Male | 48 | 0.0 |
Middle Aged | 40 | 0.0 |
Reference Values | 4 | 0.0 |
Risk Factors | 2 | 0.0 |
English Abstract | 4 | 0.0 |
Aged | 38 | 0.0 |
Aged, 80 and over | 15 | 0.0 |
CA-15-3 Antigen/biosynthesis | 2 | 18.0 |
Immunohistochemistry | 46 | 0.0 |
Mucins/*biosynthesis | 5 | 13.0 |
Research Support, Non-U.S. Gov't | 82 | 0.0 |
CA-15-3 Antigen/metabolism | 5 | 15.0 |
Helicobacter Infections/*metabolism | 2 | 16.0 |
*Helicobacter pylori | 5 | 4.0 |
Immunoenzyme Techniques | 17 | 0.0 |
Lewis Blood-Group System/*metabolism | 3 | 37.0 |
Mucins/*metabolism | 13 | 13.0 |
Base Sequence | 15 | 0.0 |
DNA Primers | 4 | 0.0 |
Mucins/biosynthesis/*genetics | 2 | 11.0 |
Polymerase Chain Reaction | 3 | 0.0 |
Tumor Cells, Cultured | 7 | 0.0 |
Gastric Mucosa/metabolism/pathology | 4 | 19.0 |
Hyperplasia | 3 | 0.0 |
Intestinal Mucosa/pathology | 2 | 3.0 |
Mucins/metabolism | 5 | 10.0 |
CA-15-3 Antigen/analysis | 4 | 6.0 |
Lymphatic Metastasis | 5 | 0.0 |
Mucins/*analysis | 10 | 26.0 |
Gene Expression | 11 | 0.0 |
In Situ Hybridization | 27 | 0.0 |
Neoplasm Proteins/biosynthesis/genetics | 2 | 1.0 |
RNA, Messenger/genetics/metabolism | 4 | 0.0 |
Reverse Transcriptase Polymerase Chain Reaction | 17 | 0.0 |
Centrifugation, Density Gradient | 3 | 0.0 |
Enzyme-Linked Immunosorbent Assay | 8 | 0.0 |
Glycosylation | 8 | 0.0 |
Stomach/*metabolism | 2 | 11.0 |
Tissue Distribution | 2 | 0.0 |
Metaplasia/metabolism/pathology | 2 | 25.0 |
Mucins/classification/*metabolism | 3 | 75.0 |
Stomach Neoplasms/metabolism/pathology | 2 | 28.0 |
Neoplasm Staging | 3 | 0.0 |
Retrospective Studies | 4 | 0.0 |
Tumor Markers, Biological | 3 | 0.0 |
CA-19-9 Antigen/analysis | 2 | 15.0 |
Keratin/analysis | 4 | 1.0 |
Mucins/analysis | 8 | 22.0 |
Cholelithiasis/chemistry/*metabolism | 2 | 100.0 |
Epithelium/metabolism | 9 | 2.0 |
Gallbladder/*metabolism | 4 | 30.0 |
Molecular Sequence Data | 19 | 0.0 |
Mucins/*genetics | 25 | 22.0 |
RNA, Messenger/analysis | 12 | 0.0 |
Adenocarcinoma/*genetics | 2 | 1.0 |
Chronic Disease | 3 | 0.0 |
Comparative Study | 16 | 0.0 |
Gene Expression Regulation | 3 | 0.0 |
*Gene Expression Regulation, Neoplastic | 6 | 0.0 |
Mucins/analysis/*genetics | 3 | 20.0 |
Research Support, U.S. Gov't, P.H.S. | 14 | 0.0 |
Tumor Markers, Biological/*analysis | 5 | 0.0 |
CA-15-3 Antigen/*analysis | 3 | 17.0 |
Prognosis | 9 | 0.0 |
Protein p53/analysis | 2 | 0.0 |
Biological Markers/analysis | 3 | 0.0 |
Diagnosis, Differential | 3 | 0.0 |
*Gene Expression Profiling | 3 | 0.0 |
Phenotype | 7 | 0.0 |
Case-Control Studies | 5 | 0.0 |
Colorectal Neoplasms/*genetics | 2 | 0.0 |
Immunohistochemistry/methods | 4 | 0.0 |
Statistics, Nonparametric | 2 | 0.0 |
Cell Differentiation | 9 | 0.0 |
Gastric Mucin/analysis | 2 | 66.0 |
Metaplasia | 8 | 8.0 |
Multivariate Analysis | 2 | 0.0 |
Neoplasm Proteins/*analysis | 2 | 0.0 |
Organ Specificity | 5 | 0.0 |
Stomach/*chemistry | 2 | 33.0 |
Survival Analysis | 3 | 0.0 |
Survival Rate | 3 | 0.0 |
Adolescent | 4 | 0.0 |
Cell Line | 5 | 0.0 |
Epithelial Cells/metabolism | 4 | 1.0 |
Amino Acid Sequence | 15 | 0.0 |
Cloning, Molecular | 6 | 0.0 |
Mucins/*chemistry/*genetics | 2 | 100.0 |
Restriction Mapping | 3 | 0.0 |
Sequence Alignment | 4 | 0.0 |
Sequence Homology, Amino Acid | 2 | 0.0 |
Trachea/metabolism | 2 | 11.0 |
Animals | 13 | 0.0 |
CA-15-3 Antigen/genetics | 2 | 14.0 |
Cattle | 3 | 0.0 |
*Gene Expression | 6 | 0.0 |
Salivary Proteins/genetics | 2 | 40.0 |
Chromosome Mapping | 3 | 0.0 |
Gastric Mucosa/pathology | 3 | 7.0 |
Gastric Mucin/*metabolism | 4 | 50.0 |
Gestational Age | 5 | 0.0 |
*Gastrectomy | 2 | 8.0 |
Disease Progression | 2 | 0.0 |
Antibody Specificity | 2 | 0.0 |
*Gene Expression Regulation | 3 | 0.0 |
Predictive Value of Tests | 2 | 0.0 |
RNA, Messenger/biosynthesis | 2 | 0.0 |
*Muscle Proteins | 8 | 2.0 |
*Neuropeptides | 8 | 6.0 |
Peptides/*analysis | 2 | 2.0 |
Pyloric Antrum | 2 | 50.0 |
Mucins/genetics/*metabolism | 9 | 23.0 |
RNA, Messenger/metabolism | 12 | 0.0 |
Stomach Neoplasms/*metabolism | 2 | 4.0 |
Mucins/*genetics/metabolism | 5 | 17.0 |
Growth Substances/*metabolism | 3 | 2.0 |
Peptides/*metabolism | 5 | 2.0 |
In Situ Hybridization, Fluorescence | 2 | 0.0 |
Keratin/*metabolism | 2 | 6.0 |
Tumor Markers, Biological/metabolism | 3 | 0.0 |
Caco-2 Cells | 2 | 0.0 |
Hydrogen-Ion Concentration | 4 | 0.0 |
Metaplasia/metabolism | 2 | 15.0 |
RNA, Messenger/genetics | 3 | 0.0 |
Antigens, Tumor-Associated, Carbohydrate/genetics/immunology/*metabolism | 2 | 100.0 |
Up-Regulation | 5 | 0.0 |
CA-15-3 Antigen/genetics/metabolism | 2 | 33.0 |
Mucins/*genetics/*metabolism | 3 | 37.0 |
Tumor Markers, Biological/*metabolism | 5 | 1.0 |
Research Support, U.S. Gov't, Non-P.H.S. | 11 | 0.0 |
Blotting, Western | 10 | 0.0 |
Neoplasm Invasiveness/pathology | 2 | 3.0 |
Neoplasm Proteins/*metabolism | 4 | 0.0 |
Stomach Neoplasms/*metabolism/pathology | 5 | 8.0 |
Electrophoresis, Polyacrylamide Gel | 5 | 0.0 |
Gastric Mucosa/metabolism | 2 | 4.0 |
Mice | 6 | 0.0 |
Antibodies, Monoclonal | 3 | 0.0 |
Biopsy | 4 | 0.0 |
Gastric Mucosa/*metabolism/pathology | 3 | 23.0 |
Transfection | 3 | 0.0 |
Cell Transformation, Neoplastic | 2 | 0.0 |
Precancerous Conditions/*metabolism/pathology | 2 | 9.0 |
Gallbladder Neoplasms/metabolism/*pathology | 2 | 40.0 |
Blotting, Northern | 5 | 0.0 |
Digestive System/*metabolism | 2 | 5.0 |
Gene Expression Regulation, Neoplastic | 7 | 0.0 |
*Gene Expression Regulation, Developmental | 2 | 0.0 |
RNA, Messenger/*metabolism | 3 | 0.0 |
Adenocarcinoma, Mucinous/genetics/*metabolism/pathology | 2 | 66.0 |
DNA Mutational Analysis | 2 | 0.0 |
Ki-67 Antigen/metabolism | 2 | 0.0 |
Mutation | 2 | 0.0 |
Cell Division | 2 | 0.0 |
Adenocarcinoma/metabolism/*pathology | 2 | 3.0 |
Adenoma/metabolism/pathology | 2 | 7.0 |
Breast Neoplasms/*metabolism | 2 | 0.0 |
Carcinoma/*metabolism | 2 | 2.0 |
Chromosomes, Human, Pair 11/*genetics | 3 | 1.0 |
Genomic Library | 3 | 0.0 |
Chromosomes, Human, Pair 11/genetics | 2 | 0.0 |
Dimerization | 2 | 0.0 |
*Multigene Family | 3 | 0.0 |
Neoplasm Invasiveness | 3 | 0.0 |
Child | 4 | 0.0 |
Bile Ducts, Intrahepatic/*metabolism/pathology | 2 | 33.0 |
Blotting, Southern | 3 | 0.0 |
Molecular Weight | 2 | 0.0 |
Fluorescent Antibody Technique, Indirect | 2 | 0.0 |
Mucins/*biosynthesis/metabolism | 2 | 40.0 |
Precipitin Tests | 2 | 0.0 |
Introns | 2 | 0.0 |
Repetitive Sequences, Nucleic Acid | 5 | 0.0 |
Sequence Analysis, DNA | 2 | 0.0 |
Colorectal Neoplasms/metabolism/*pathology | 2 | 9.0 |
Adenocarcinoma, Mucinous/*metabolism/pathology | 2 | 28.0 |
Microscopy, Electron | 2 | 0.0 |
Anti-Bacterial Agents/therapeutic use | 2 | 1.0 |
Colon/metabolism | 2 | 1.0 |
Protein Binding | 2 | 0.0 |
Transplantation, Heterologous | 2 | 0.0 |
Adenocarcinoma/classification/*metabolism/pathology | 2 | 40.0 |
Tumor Markers, Biological/analysis | 2 | 0.0 |
Carcinoembryonic Antigen/analysis | 2 | 1.0 |
Infant | 3 | 0.0 |
Antibodies, Monoclonal/immunology | 2 | 0.0 |
Neoplasm Metastasis | 2 | 0.0 |
Neoplasm Proteins/metabolism | 2 | 0.0 |
Child, Preschool | 2 | 0.0 |
Gene Expression/*genetics | 2 | 1.0 |
